EROSION II: OCT Guided PPCI in STEMI

Summary

This protocol describes a prospective, multi-center study intended to test the hypothesis that patients with STEMI caused by plaque rupture or plaque erosion without obstructive stenosis (diameter stenosis \<70%) can be stabilized by effective antithrombotic treatment without stent implantation, thereby avoiding both early and late complications related to percutaneous coronary intervention (PCI) with stent implantation. All the patients will be followed by intracoronary OCT and physiological assessment at 1-month and 12-month follow-up.

Conditions

• ST-segment Elevation Myocardial Infarction

Interventions

DRUG

dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel)

Patients who met the inclusion criteria will be treated with dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel).

Sponsors & Collaborators

• Shenzhen Salubris Pharmaceuticals Co., Ltd.

  collaborator INDUSTRY

• Beijing Luhe Hospital

  collaborator OTHER

• The First Hospital of Jilin University

  collaborator OTHER

• China-Japan Union Hospital, Jilin University

  collaborator OTHER

• The First Affiliated Hospital of Dalian Medical University

  collaborator OTHER

• Shanxi Cardiovascular Hospital

  collaborator OTHER

• Second Hospital of Shanxi Medical University

  collaborator OTHER

• Hebei General Hospital

  collaborator OTHER

• General Hospital of Ningxia Medical University

  collaborator OTHER

• Sichuan Provincial People's Hospital

  collaborator OTHER

• Affiliated Hospital of Jiangsu University

  collaborator OTHER

• Xiamen Cardiovascular Hospital, Xiamen University

  collaborator OTHER

• Shenzhen Sun Yat-sen Cardiovascular Hospital

  collaborator OTHER

• LanZhou University

  collaborator OTHER

• Sir Run Run Shaw Hospital

  collaborator OTHER

• Wuhan Asia Heart Hospital

  collaborator OTHER

• Harbin Medical University

  lead OTHER

Principal Investigators

• Bo YU, MD, PhD · The Second Affiliated Hospital of Harbin Medical University

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2017-01-11

Primary Completion

2022-02-24

Completion

2023-03-01

Countries

• China

Study Locations